Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Aug 21:2021.08.19.21262111.
doi: 10.1101/2021.08.19.21262111.

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Ariel Israel  1 , Yotam Shenhar  1 , Ilan Green  1   2 , Eugene Merzon  1   2 , Avivit Golan-Cohen  1   2 , Alejandro A Schäffer  3 , Eytan Ruppin  3 , Shlomo Vinker  1   2 , Eli Magen  1   4
Affiliations

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Ariel Israel et al. medRxiv. .

Update in

Abstract

Background: Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time.

Objective: To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals.

Methods: Antibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine.

Results: A total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.

Conclusions: This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.

Funding: This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Impact statement: Large scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest disclosure statement: All authors have no conflicts to disclose

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. The authors declare no competing interests. AI, YS, EM, IG, AGC, SV and EM are employees of Leumit Health Services. All authors declare that they have no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1a.
Figure 1a.
Figure 1b.
Figure 1b.
Figure 2a.
Figure 2a.
Figure 2b.
Figure 2b.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Abbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity™ i System - May 11, 2020. n.d. https://abbott.mediaroom.com/2020-05-11-Abbott-Receives-FDA-Emergency-Us...
    1. Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, Rijnink W, Alshammary H, Borcherding N, Reiche AG, Srivastava K, Sordillo EM, van Bakel H, Personalized Virology Initiative, Turner JS, Bajic G, Simon V, Ellebedy AH, Krammer F. 2021. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184:3936–3948.e10. doi:10.1016/j.cell.2021.06.005 - DOI - PMC - PubMed
    1. Breuer A, Raphael A, Stern H, Odeh M, Fiszlinski J, Algur N, Magen S, Megged O, Schlesinger Y, Barak-Corren Y, Heiman E. 2021. SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population. Acta Paediatr 00:1–9. doi:10.1111/APA.16031 - DOI - PMC - PubMed
    1. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol 58. doi:10.1128/JCM.00941-20 - DOI - PMC - PubMed
    1. Chakraborty C, Bhattacharya M, Sharma AR. 2021. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Rev Med Virol e2270. doi:10.1002/RMV.2270 - DOI

Publication types